TiGenix says it's on track for 2017 EMA decision on Cx601

6 March 2017

TiGenix (Euronext: TIG) says it has received a Day 180 List of Outstanding Issues (LoOI) notice from the European Medicine Agency for its experimental gastro-intestinal candidate Cx601.

The drug is being developed for the treatment of perianal fistulas in patients with Crohn’s disease. The Leuven, Belgium-based specialty biopharmaceutical company did not say what was on the letter, but stated: “After reviewing the LoOI, we are confident in our ability to provide detailed and clarifying responses to the EMA and remain on track to receive a Marketing Authorization decision for Cx601 in 2017.”

The company’s application has been paused - known as a "clock stop" period - while the company prepares its response. The Day 180 LoOI letter is a standard part of the EMA’s regulatory approval process.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK